26 recruiting, 16 active not recruiting, 6 not yet recruiting, 1 approved for marketing. 25 Phase 2, 13 Phase 1, 12 Phase 3, 2 Phase 4.
Follow Teclistamab: new trials by email Literature Review of Teclistamab trials Research Report on Teclistamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-23 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | 248 | 2026-09-01 | 2026-07-31 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| GMMG-HD11/DSMM XXI/64007957MMY3010 Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Not yet recruiting | University of Heidelberg Medical Center | 399 | 2026-06-30 | 2026-06-26 |
| Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma Sirolimus, Teclistamab, Talquetamb - Multiple Myeloma | Phase 1 | Recruiting | Christopher Strouse | 10 | 2026-06-01 | 2026-06-04 |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322, Teclistamab - Multiple Myeloma | Phase 3 | Recruiting | Janssen Research & Development, LLC | 700 | 2026-05-31 | 2026-09-25 |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322, Teclistamab - Multiple Myeloma | Phase 3 | Recruiting | Janssen Research & Development, LLC | 400 | 2026-02-04 | 2026-09-25 |
| Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. Teclistamab, Talquetamab, Daratumumab - Multiple Myeloma (MM) | Phase 2 | Recruiting | European Myeloma Network B.V. | 150 | 2025-12-12 | 2026-04-15 |
| Teclistamab-Daratumumab in AL Amyloidosis Teclistamab, Daratumumab and Hyaluronidase-fihj - Amyloid Light-chain Amyloidosis | Phase 2 | Recruiting | Rajshekhar Chakraborty, MD | 25 | 2025-11-07 | 2026-07-13 |
| Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma Teclistamab - Multiple Myleoma, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 52 | 2025-11-01 | 2025-04-03 |
| Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) Talquetamab, Teclistamab - Multiple Myeloma | Phase 2 | Recruiting | Noffar Bar | 50 | 2025-08-21 | 2026-05-13 |
| A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma Teclistamab, Mezigdomide - Multiple Myeloma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2025-08-08 | 2026-10-13 |
Showing 20 of 52. Sign in to see all of them.
Multiple Myeloma (43) · Recurrence (7) · Immunoglobulin Light-chain Amyloidosis (4) · Hematologic Neoplasms (3) · Leukemia, Plasma Cell (3) · Cytokine Release Syndrome (2) · Neoplasm, Residual (2) · Neoplasms (2) · Frailty (1) · Hematologic Diseases (1) · Infections (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms, Plasma Cell (1)
Janssen Research & Development, LLC (15) · National Cancer Institute (NCI) (5) · European Myeloma Network B.V. (3) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · Carl Ola Landgren, MD, PhD (1) · CellCentric Ltd. (1) · Christopher Strouse (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Irene Ghobrial, MD (1) · Janssen Pharmaceutical K.K. (1) · Janssen-Cilag Ltd. (1) · Johnson & Johnson Private Limited (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1)
United States (32) · France (17) · Spain (17) · Germany (15) · Canada (13) · Italy (13) · United Kingdom (13) · Australia (12) · Netherlands (11) · China (9) · Greece (9) · Israel (9) · Belgium (8) · Brazil (8) · Japan (8)
Alessandra Larocca (1) · Andrew Branagan, MD, PhD (1) · Carl O Landgren, MD, PhD (1) · Charlotte Pawlyn (1) · Christine Chen, Dr. (1) · Christopher Strouse, MD (1) · Diana Loigom, MD (1) · Douglas W Sborov (1) · Elena Zamagni, Professor (1) · Francesco Zaja (1) · Fredrik Schjesvold (1) · Gordon Cook (1)
PMID 41485109, PMID 32956453, PMID 35661166, PMID 36961654, PMID 36991547, PMID 37132225, PMID 37173224, PMID 37713090, PMID 37960969, PMID 38052042, PMID 38052709, PMID 38110653, PMID 38657201, PMID 39172760, PMID 39778168, PMID 40332715, PMID 40495704, PMID 40983036, PMID 41358582, PMID 41363801, PMID 41574880, PMID 41886220, PMID 42212933, PMID 42273947, PMID 42534634, PMID 42685673, PMID 42728379
2023 (10), 2025 (3), 2019 (2), U10CA180820 (2), 2016 (1), U10CA180821 (1), UM1CA186709 (1), UM1CA186717 (1)